SEQUENCE LISTING

<110> Protherics Molecular Design Limited

<120> CJD Prion testing

<130> 444.39.83372/01

<140> PCT/GB05/000328
<141> 2005-01-27

<150> GB0402123.4
<151> 2004-01-30

<160> 4

<170> PatentIn version 3.0

<210> 1
<211> 29
<212> PRT
<213> synthetic construct

<220>
<221> SITE
<222> (9)..(9)
<223> Xaa is Gly or is absent

<220>
<221> SITE
<222> (10)..(10)
<223> Xaa is Thr or Ser

<220>
<221> SITE
<222> (12)..(12)
<223> Xaa is Gly, Ser or Asn

<220>

<221>   SITE

<222>   (18)..(18)

<223>   Xaa is Asn or Ser

<220>

<221>   SITE

<222>   (23)..(23)

<223>   Xaa is Asn or Ser

<220>

<221>   SITE

<222>   (24)..(24)

<223>   Xaa is Met, Leu or Phe

<220>

<221>   SITE

<222>   (27)..(27)

<223>   Xaa is Val or Met

<220>

<221>   SITE

<222>   (1)..(4)

<223>   One or more of these residues may be present or absent with the
         proviso that if they are present they are attached to the rest
of
         the peptide in sequence

<220>

<221>   SITE

<222>   (26)..(29)

<223>   One or more of these residues may be present or absent with the
         proviso that if they are present they are attached to the rest
of
         the peptide in sequence

<400> 1

Gly Gly Gly Trp Gly Gln Gly Gly Xaa Xaa His Xaa Gln Trp Asn Lys
1   5   10   15

Pro Xaa Lys Pro Lys Thr Xaa Xaa Lys His Xaa Ala Gly
        20   25

<210> 2
<211> 24
<212> PRT
<213> synthetic construct

<400> 2

Gly Gln Gly Gly Ser His Ser Gln Trp Asn Lys Pro Ser Lys Pro Lys
1   5   10   15

Thr Asn Met Lys His Val Gly Cys
            20

<210> 3
<211> 31
<212> PRT
<213> synthetic construct

<220>
<221> SITE
<222> (4)..(4)
<223> Xaa is Gly or is absent

<220>
<221> SITE
<222> (29)..(29)
<223> Xaa is Gly or is absent

<220>
<221> SITE
<222> (30)..(30)
<223> Xaa is Gly or Thr

<220>
<221> SITE
<222> (1)..(4)
<223> One or more of these residues may be present or absent with the

of   proviso that if they are present they are attached to the rest
        the peptide in sequence

<220>

<221> SITE

<222> (28)..(31)

<223> One or more of these residues may be present or absent with the
of   proviso that if they are present they are attached to the rest
        the peptide in sequence

<400> 3
Pro Gly Gly Xaa Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly
1   5   10   15
Ser Pro Gly Gly Asn Arg Tyr Pro Pro Gln Gly Gly Xaa Xaa Trp
            20   25   30

<210> 4

<211> 28

<212> PRT

<213> synthetic construct

<400> 4
Gly Gly Trp Asn Thr Gly Gly Ser Arg Tyr Pro Gly Gln Gly Ser Pro
1   5   10   15
Gly Gly Asn Arg Tyr Pro Pro Gln Gly Gly Gly Cys
            20   25